These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32046665)

  • 1. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    Eppenberger-Castori S; Klingbiel D; Ruhstaller T; Dietrich D; Rufle DA; Rothgiesser K; Pagani O; Thürlimann B
    BMC Cancer; 2020 Feb; 20(1):114. PubMed ID: 32046665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
    Kontani K; Kuroda N; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Kushida Y; Date M; Haba R; Houchi H; Yamauchi A; Yokomise H
    Cancer Biol Ther; 2013 Jan; 14(1):20-8. PubMed ID: 23114645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
    Pagani O; Klingbiel D; Ruhstaller T; Nolè F; Eppenberger S; Oehlschlegel C; Bernhard J; Brauchli P; Hess D; Mamot C; Munzone E; Pestalozzi B; Rabaglio M; Aebi S; Ribi K; Rochlitz C; Rothgiesser K; Thürlimann B; von Moos R; Zaman K; Goldhirsch A;
    Ann Oncol; 2017 Feb; 28(2):305-312. PubMed ID: 27998961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
    Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
    [No Abstract]   [Full Text] [Related]  

  • 7. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
    Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
    Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
    Schmid S; Klingbiel D; Aebi S; Goldhirsch A; Mamot C; Munzone E; Nolè F; Oehlschlegel C; Pagani O; Pestalozzi B; Rochlitz C; Thürlimann B; von Moos R; Weder P; Zaman K; Ruhstaller T
    BMC Cancer; 2019 Sep; 19(1):902. PubMed ID: 31500588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.